/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

K

Konstantin Penkov

City Clinical Hospital No 31(RU)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

53

Papers

4.2K

Citations

18

h-index

20

i10-index

Konstantin Penkov is an academic researcher from City Clinical Hospital No 31. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Renal cell carcinoma treatment & Lung Cancer Research Studies. The author has an h-index of 18, co-authored 46 publications.

Research Topics

Cancer Immunotherapy and Biomarkers Renal cell carcinoma treatment Lung Cancer Research Studies Lung Cancer Treatments and Mutations Prostate Cancer Treatment and Research

Papers by this author

works

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

2019 · New England Journal of Medicine · 2,479 citations

https://doi.org/10.1056/nejmoa1816047

Robert J. Motzer Konstantin Penkov John B.A.G. Haanen Brian I. Rini

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

2021 · Journal of Thoracic Oncology · 244 citations

https://doi.org/10.1016/j.jtho.2021.02.009

Fiona Blackhall Kevin Jao Laurent Greillier Byoung Chul Cho

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

2023 · ESMO Open · 52 citations

https://doi.org/10.1016/j.esmoop.2023.101210

John B.A.G. Haanen James Larkin Toni K. Choueiri Laurence Albigès

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial

2024 · Annals of Oncology · 40 citations

https://doi.org/10.1016/j.annonc.2024.12.008

Toni K. Choueiri Konstantin Penkov Hiroji Uemura Matthew T. Campbell

Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).

2024 · Journal of Clinical Oncology · 11 citations

https://doi.org/10.1200/jco.2024.42.16_suppl.5061

Michael T. Schweizer Konstantin Penkov Atish D. Choudhury Emiliano Calvo

A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

2023 · ESMO Open · 5 citations

https://doi.org/10.1016/j.esmoop.2023.101589

Byoung Chul Cho Konstantin Penkov Igor Bondarenko A. Kurochkin

Research topics

topics

Cancer Immunotherapy and Biomarkers

Renal cell carcinoma treatment

Lung Cancer Research Studies

Lung Cancer Treatments and Mutations

Prostate Cancer Treatment and Research

Chat about Author

Papers

Chat

Click to start Chat